ARCpoint Inc (ARC) Fair Value & Analysis
Technology · CA · Market cap 10.1M GBX
Fair value as of: Jun 24, 2026
Analysis
ARCpoint Inc (ARC) currently trades at p0.7750, while our model-based Fair Value estimate is p1.41 — implying the stock looks roughly 81.9% undervalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
ARCpoint Inc. provides franchise systems offering drug, alcohol, DNA, and clinical lab testing and screening services in the United States. It operates in two segments, ARCpoint Franchise and AFG Services. The company offers viral testing for viruses, such as Flu, Strep, and covid; regulatory compliance testing; ailments testing; preventive care services, including annual health, heart health, thyroid, diabetes, and hormone testing; nutritional testing comprising food allergy/sensitivity and vitamin/nutrient deficiency testing; and specialty health solutions such as TB and titer, pregnancy - related, respiratory/allergy, and blood type testing services, as well as vaccine, vitamin and supplements injections. It also provides drug, alcohol, and on-site mobile testing; paternity and DNA services; STD; and dry eyes testing services. In addition, the company offers employer solutions consisting of DOT solutions, background screening, HR employment solutions, and employee assistance prog…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is ARCpoint Inc (ARC) undervalued?
What is the fair value of ARC?
What is the quality score of ARC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.